<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8213933</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">33998178</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">8213933</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1002/brb3.2174</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">BRB32174</article-id></all-ids><extracted-table><table-id>brb32174-tbl-0001</table-id><table-label>TABLE 1</table-label><table-caption>Twenty biggest CAP group differences in FSL randomise TFCE clusters (false discovery rate q &lt; 0.05 corrected, two‐tailed FDR‐adjusted p‐value threshold p =.002) and percentage of brain areas in each CAP and IC in which the ASD or TD groups had significantly greater values than the other group</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="brb32174-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Twenty biggest CAP group differences in FSL randomise TFCE clusters (false discovery rate q &lt; 0.05 corrected, two‐tailed FDR‐adjusted <italic>p</italic>‐value threshold <italic>p</italic> =.002) and percentage of brain areas in each CAP and IC in which the ASD or TD groups had significantly greater values than the other group</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">CAP</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">VOXELS</th><th align="left" valign="top" rowspan="1" colspan="1">CLUSTERS</th><th align="left" valign="top" rowspan="1" colspan="1">ICA‐AREAS by % (voxels of clusters area/ICA area)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">06–06</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">9,565</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">DMN/Language, 57% (1298/2259); DMN‐A, 46% (900/1951); Auditory/VAN‐P, 46% (1086/2356); DMN‐D, 45% (419/926); Motor, 37% (1113/2998); Visual Lat, 35% (530/1518); Visual Med, 32% (766/2375); DMN‐V, 29% (454/1581); Somatosensory, 28% (759/2716); Salience/VAN‐A, 25% (643/2523); FPC R, 24% (806/3403); FPC L, 20% (423/2143); Visual Up Med, 13% (149/1150); DAN, 12% (212/1769);</td></tr><tr><td align="left" rowspan="1" colspan="1">13–11</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">6,027</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Salience/VAN‐A, 43% (1087/2523); FPC L, 38% (819/2143); Auditory/VAN‐P, 36% (846/2356); Somatosensory, 32% (873/2716); Visual Lat, 26% (390/1518); FPC R, 19% (636/3403); DAN, 18% (310/1769); Motor, 12% (362/2998); DMN‐V, 9% (136/1581); DMN‐D, 9% (80/926); DMN‐A, 9% (168/1951); Visual Med, 6% (133/2375); DMN/Language, 6% (143/2259); Visual Up Med, 4% (44/1150);</td></tr><tr><td align="left" rowspan="1" colspan="1">02–01</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">5,631</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">DMN‐V, 41% (653/1581); DMN‐D, 30% (278/926); Visual Med, 27% (650/2375); DMN‐A, 27% (529/1951); Visual Up Med, 26% (298/1150); FPC R, 23% (797/3403); DAN, 22% (394/1769); DMN/Language, 19% (420/2259); Somatosensory, 18% (484/2716); Visual Lat, 12% (175/1518); Motor, 12% (355/2998); Salience/VAN‐A, 10% (244/2523); Auditory/VAN‐P, 9% (223/2356); FPC L, 6% (119/2143);</td></tr><tr><td align="left" rowspan="1" colspan="1">25–22</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">5,618</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">Somatosensory, 44% (1185/2716); DAN, 34% (608/1769); Visual Med, 31% (739/2375); DMN‐V, 25% (392/1581); FPC L, 24% (504/2143); Visual Up Med, 22% (251/1150); Visual Lat, 18% (268/1518); Auditory/VAN‐P, 18% (423/2356); Motor, 16% (468/2998); DMN/Language, 13% (289/2259); DMN‐D, 10% (96/926); Salience/VAN‐A, 6% (158/2523); DMN‐A, 5% (106/1951); FPC R, 4% (131/3403);</td></tr><tr><td align="left" rowspan="1" colspan="1">06–03</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">5,476</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Salience/VAN‐A, 40% (1014/2523); Auditory/VAN‐P, 39% (930/2356); DAN, 25% (451/1769); Visual Med, 24% (568/2375); FPC L, 24% (513/2143); FPC R, 18% (623/3403); DMN‐D, 17% (158/926); Visual Lat, 12% (180/1518); DMN‐V, 11% (171/1581); Somatosensory, 8% (220/2716); DMN/Language, 8% (190/2259); DMN‐A, 8% (162/1951); Motor, 7% (222/2998); Visual Up Med, 6% (72/1150);</td></tr><tr><td align="left" rowspan="1" colspan="1">19–16</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">5,445</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">DMN/Language, 46% (1040/2259); DMN‐D, 40% (373/926); DMN‐A, 31% (604/1951); Visual Lat, 25% (382/1518); Visual Med, 19% (462/2375); Auditory/VAN‐P, 19% (440/2356); DMN‐V, 15% (235/1581); FPC R, 14% (463/3403); FPC L, 14% (294/2143); Salience/VAN‐A, 13% (335/2523); Motor, 13% (375/2998); DAN, 9% (157/1769); Visual Up Med, 7% (82/1150); Somatosensory, 7% (191/2716);</td></tr><tr><td align="left" rowspan="1" colspan="1">28–25</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">5,340</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Salience/VAN‐A, 32% (819/2523); Visual Lat, 30% (460/1518); FPC L, 27% (569/2143); Auditory/VAN‐P, 25% (588/2356); DAN, 24% (418/1769); Somatosensory, 22% (590/2716); DMN‐D, 18% (163/926); Visual Med, 13% (313/2375); DMN/Language, 13% (295/2259); FPC R, 12% (414/3403); DMN‐A, 11% (207/1951); DMN‐V, 10% (166/1581); Visual Up Med, 8% (94/1150); Motor, 8% (244/2998);</td></tr><tr><td align="left" rowspan="1" colspan="1">08–04</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">5,248</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Auditory/VAN‐P, 45% (1057/2356); Salience/VAN‐A, 28% (713/2523); Visual Med, 24% (574/2375); DMN/Language, 23% (519/2259); FPC R, 21% (729/3403); Visual Lat, 15% (231/1518); DAN, 14% (254/1769); FPC L, 11% (226/2143); DMN‐A, 11% (208/1951); Motor, 10% (305/2998); DMN‐V, 10% (158/1581); Visual Up Med, 7% (77/1150); Somatosensory, 6% (151/2716); DMN‐D, 5% (46/926);</td></tr><tr><td align="left" rowspan="1" colspan="1">12–02</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">5,126</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">DMN/Language, 39% (875/2259); Salience/VAN‐A, 28% (699/2523); DMN‐A, 23% (455/1951); Auditory/VAN‐P, 21% (484/2356); DMN‐V, 19% (294/1581); DMN‐D, 18% (166/926); FPC R, 16% (545/3403); Visual Med, 15% (363/2375); Visual Lat, 14% (217/1518); FPC L, 12% (257/2143); Visual Up Med, 11% (124/1150); Motor, 11% (332/2998); DAN, 9% (155/1769); Somatosensory, 6% (158/2716);</td></tr><tr><td align="left" rowspan="1" colspan="1">05–02</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">4,863</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">DMN‐V, 40% (632/1581); DMN‐A, 40% (776/1951); DMN‐D, 39% (364/926); DMN/Language, 27% (603/2259); FPC R, 25% (859/3403); Visual Med, 16% (384/2375); Salience/VAN‐A, 12% (301/2523); Visual Up Med, 11% (123/1150); Visual Lat, 11% (168/1518); FPC L, 11% (246/2143); Auditory/VAN‐P, 8% (180/2356); DAN, 6% (114/1769); Motor, 2% (67/2998); Somatosensory, 1% (36/2716);</td></tr><tr><td align="left" rowspan="1" colspan="1">19–18</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">4,693</td><td align="char" char="." rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">Auditory/VAN‐P, 38% (907/2356); FPC R, 26% (894/3403); DMN/Language, 26% (579/2259); DMN‐V, 19% (299/1581); DMN‐D, 19% (173/926); Somatosensory, 15% (412/2716); Motor, 14% (425/2998); Salience/VAN‐A, 13% (317/2523); DMN‐A, 12% (228/1951); FPC L, 11% (234/2143); Visual Up Med, 7% (78/1150); Visual Med, 3% (76/2375); Visual Lat, 2% (36/1518); DAN, 2% (35/1769);</td></tr><tr><td align="left" rowspan="1" colspan="1">09–08</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">4,525</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">Somatosensory, 34% (915/2716); Visual Up Med, 28% (321/1150); DMN‐V, 24% (375/1581); Visual Med, 20% (481/2375); Motor, 17% (502/2998); Visual Lat, 15% (231/1518); FPC L, 15% (322/2143); DAN, 13% (223/1769); Auditory/VAN‐P, 13% (304/2356); DMN‐A, 11% (220/1951); DMN‐D, 10% (93/926); Salience/VAN‐A, 9% (236/2523); DMN/Language, 8% (188/2259); FPC R, 3% (108/3403);</td></tr><tr><td align="left" rowspan="1" colspan="1">04–03</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">4,472</td><td align="char" char="." rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">DMN/Language, 28% (630/2259); Somatosensory, 23% (614/2716); FPC R, 21% (708/3403); DMN‐V, 21% (328/1581); Motor, 19% (568/2998); DMN‐D, 17% (156/926); Visual Up Med, 14% (157/1150); FPC L, 11% (227/2143); Auditory/VAN‐P, 10% (236/2356); Visual Med, 9% (223/2375); DMN‐A, 9% (185/1951); Salience/VAN‐A, 8% (200/2523); DAN, 8% (143/1769); Visual Lat, 6% (89/1518);</td></tr><tr><td align="left" rowspan="1" colspan="1">16–06</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">4,426</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">DMN‐D, 46% (426/926); DMN‐A, 32% (622/1951); DMN‐V, 29% (459/1581); DMN/Language, 24% (542/2259); FPC R, 20% (695/3403); Auditory/VAN‐P, 20% (477/2356); Visual Lat, 11% (163/1518); FPC L, 10% (210/2143); Visual Med, 8% (179/2375); Somatosensory, 8% (216/2716); Motor, 7% (213/2998); DAN, 5% (81/1769); Salience/VAN‐A, 4% (103/2523); Visual Up Med, 3% (39/1150);</td></tr><tr><td align="left" rowspan="1" colspan="1">03–03</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">4,187</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">Visual Med, 28% (667/2375); DAN, 26% (452/1769); Somatosensory, 24% (652/2716); Auditory/VAN‐P, 21% (487/2356); DMN‐V, 19% (301/1581); Visual Up Med, 14% (160/1150); Motor, 14% (426/2998); DMN/Language, 12% (263/2259); DMN‐D, 11% (103/926); Visual Lat, 9% (134/1518); FPC R, 7% (246/3403); Salience/VAN‐A, 6% (140/2523); FPC L, 4% (94/2143); DMN‐A, 3% (62/1951);</td></tr><tr><td align="left" rowspan="1" colspan="1">05–05</td><td align="left" rowspan="1" colspan="1">ASD &gt; TD</td><td align="char" char="." rowspan="1" colspan="1">4,151</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Auditory/VAN‐P, 41% (971/2356); Salience/VAN‐A, 18% (450/2523); Motor, 18% (534/2998); Visual Med, 15% (358/2375); Somatosensory, 15% (401/2716); FPC L, 15% (319/2143); DMN/Language, 15% (345/2259); FPC R, 11% (384/3403); DAN, 10% (173/1769); DMN‐V, 4% (69/1581); DMN‐D, 4% (33/926); Visual Lat, 3% (51/1518); Visual Up Med, 2% (26/1150); DMN‐A, 2% (37/1951);</td></tr><tr><td align="left" rowspan="1" colspan="1">26–16</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">3,768</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">FPC L, 35% (748/2143); Salience/VAN‐A, 27% (682/2523); Somatosensory, 23% (620/2716); DAN, 20% (351/1769); Auditory/VAN‐P, 13% (296/2356); DMN‐V, 11% (176/1581); FPC R, 8% (257/3403); DMN‐A, 8% (149/1951); Visual Up Med, 7% (83/1150); DMN/Language, 6% (131/2259); Motor, 5% (162/2998); Visual Lat, 3% (42/1518); DMN‐D, 3% (25/926); Visual Med, 2% (46/2375);</td></tr><tr><td align="left" rowspan="1" colspan="1">21–18</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">3,663</td><td align="char" char="." rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">FPC R, 25% (866/3403); DMN‐A, 25% (483/1951); Visual Lat, 23% (345/1518); Visual Med, 21% (498/2375); DMN‐V, 17% (273/1581); DMN‐D, 15% (141/926); FPC L, 14% (291/2143); DAN, 10% (179/1769); Salience/VAN‐A, 9% (238/2523); Visual Up Med, 8% (89/1150); DMN/Language, 4% (86/2259); Motor, 3% (80/2998); Auditory/VAN‐P, 2% (42/2356); Somatosensory, 1% (39/2716);</td></tr><tr><td align="left" rowspan="1" colspan="1">13–03</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">3,564</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">DMN‐D, 31% (289/926); Visual Med, 29% (681/2375); Auditory/VAN‐P, 26% (609/2356); Salience/VAN‐A, 18% (455/2523); FPC R, 13% (434/3403); DMN/Language, 13% (300/2259); DMN‐A, 11% (217/1951); DMN‐V, 9% (144/1581); DAN, 8% (134/1769); FPC L, 6% (131/2143); Visual Up Med, 4% (43/1150); Motor, 3% (83/2998); Visual Lat, 2% (31/1518); Somatosensory, 0% (11/2716);</td></tr><tr><td align="left" rowspan="1" colspan="1">12–07</td><td align="left" rowspan="1" colspan="1">TD &gt; ASD</td><td align="char" char="." rowspan="1" colspan="1">3,538</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Visual Lat, 31% (466/1518); DMN‐A, 31% (608/1951); DMN‐D, 24% (220/926); FPC R, 22% (733/3403); Visual Med, 18% (421/2375); DMN‐V, 15% (233/1581); DAN, 9% (165/1769); Salience/VAN‐A, 8% (213/2523); FPC L, 8% (170/2143); DMN/Language, 6% (134/2259); Visual Up Med, 5% (63/1150); Auditory/VAN‐P, 3% (59/2356); Somatosensory, 1% (21/2716); Motor, 1% (23/2998);</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></original-table><transformed-table>TABLE 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Twenty biggest CAP group differences in FSL randomise TFCE clusters (false discovery rate q &lt; 0.05 corrected, two‐tailed FDR‐adjusted p‐value threshold p =.002) and percentage of brain areas in each CAP and IC in which the ASD or TD groups had significantly greater values than the other group</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top">CAP</th><th align="left" valign="top"/><th align="left" valign="top">VOXELS</th><th align="left" valign="top">CLUSTERS</th><th align="left" valign="top">ICA‐AREAS by % (voxels of clusters area/ICA area)</th></tr></thead><tbody><tr><td align="left">06–06</td><td align="left">ASD &gt; TD</td><td align="char" char=".">9,565</td><td align="char" char=".">1</td><td align="left">DMN/Language, 57% (1298/2259); DMN‐A, 46% (900/1951); Auditory/VAN‐P, 46% (1086/2356); DMN‐D, 45% (419/926); Motor, 37% (1113/2998); Visual Lat, 35% (530/1518); Visual Med, 32% (766/2375); DMN‐V, 29% (454/1581); Somatosensory, 28% (759/2716); Salience/VAN‐A, 25% (643/2523); FPC R, 24% (806/3403); FPC L, 20% (423/2143); Visual Up Med, 13% (149/1150); DAN, 12% (212/1769);</td></tr><tr><td align="left">13–11</td><td align="left">TD &gt; ASD</td><td align="char" char=".">6,027</td><td align="char" char=".">9</td><td align="left">Salience/VAN‐A, 43% (1087/2523); FPC L, 38% (819/2143); Auditory/VAN‐P, 36% (846/2356); Somatosensory, 32% (873/2716); Visual Lat, 26% (390/1518); FPC R, 19% (636/3403); DAN, 18% (310/1769); Motor, 12% (362/2998); DMN‐V, 9% (136/1581); DMN‐D, 9% (80/926); DMN‐A, 9% (168/1951); Visual Med, 6% (133/2375); DMN/Language, 6% (143/2259); Visual Up Med, 4% (44/1150);</td></tr><tr><td align="left">02–01</td><td align="left">ASD &gt; TD</td><td align="char" char=".">5,631</td><td align="char" char=".">14</td><td align="left">DMN‐V, 41% (653/1581); DMN‐D, 30% (278/926); Visual Med, 27% (650/2375); DMN‐A, 27% (529/1951); Visual Up Med, 26% (298/1150); FPC R, 23% (797/3403); DAN, 22% (394/1769); DMN/Language, 19% (420/2259); Somatosensory, 18% (484/2716); Visual Lat, 12% (175/1518); Motor, 12% (355/2998); Salience/VAN‐A, 10% (244/2523); Auditory/VAN‐P, 9% (223/2356); FPC L, 6% (119/2143);</td></tr><tr><td align="left">25–22</td><td align="left">ASD &gt; TD</td><td align="char" char=".">5,618</td><td align="char" char=".">15</td><td align="left">Somatosensory, 44% (1185/2716); DAN, 34% (608/1769); Visual Med, 31% (739/2375); DMN‐V, 25% (392/1581); FPC L, 24% (504/2143); Visual Up Med, 22% (251/1150); Visual Lat, 18% (268/1518); Auditory/VAN‐P, 18% (423/2356); Motor, 16% (468/2998); DMN/Language, 13% (289/2259); DMN‐D, 10% (96/926); Salience/VAN‐A, 6% (158/2523); DMN‐A, 5% (106/1951); FPC R, 4% (131/3403);</td></tr><tr><td align="left">06–03</td><td align="left">TD &gt; ASD</td><td align="char" char=".">5,476</td><td align="char" char=".">9</td><td align="left">Salience/VAN‐A, 40% (1014/2523); Auditory/VAN‐P, 39% (930/2356); DAN, 25% (451/1769); Visual Med, 24% (568/2375); FPC L, 24% (513/2143); FPC R, 18% (623/3403); DMN‐D, 17% (158/926); Visual Lat, 12% (180/1518); DMN‐V, 11% (171/1581); Somatosensory, 8% (220/2716); DMN/Language, 8% (190/2259); DMN‐A, 8% (162/1951); Motor, 7% (222/2998); Visual Up Med, 6% (72/1150);</td></tr><tr><td align="left">19–16</td><td align="left">ASD &gt; TD</td><td align="char" char=".">5,445</td><td align="char" char=".">8</td><td align="left">DMN/Language, 46% (1040/2259); DMN‐D, 40% (373/926); DMN‐A, 31% (604/1951); Visual Lat, 25% (382/1518); Visual Med, 19% (462/2375); Auditory/VAN‐P, 19% (440/2356); DMN‐V, 15% (235/1581); FPC R, 14% (463/3403); FPC L, 14% (294/2143); Salience/VAN‐A, 13% (335/2523); Motor, 13% (375/2998); DAN, 9% (157/1769); Visual Up Med, 7% (82/1150); Somatosensory, 7% (191/2716);</td></tr><tr><td align="left">28–25</td><td align="left">TD &gt; ASD</td><td align="char" char=".">5,340</td><td align="char" char=".">8</td><td align="left">Salience/VAN‐A, 32% (819/2523); Visual Lat, 30% (460/1518); FPC L, 27% (569/2143); Auditory/VAN‐P, 25% (588/2356); DAN, 24% (418/1769); Somatosensory, 22% (590/2716); DMN‐D, 18% (163/926); Visual Med, 13% (313/2375); DMN/Language, 13% (295/2259); FPC R, 12% (414/3403); DMN‐A, 11% (207/1951); DMN‐V, 10% (166/1581); Visual Up Med, 8% (94/1150); Motor, 8% (244/2998);</td></tr><tr><td align="left">08–04</td><td align="left">ASD &gt; TD</td><td align="char" char=".">5,248</td><td align="char" char=".">12</td><td align="left">Auditory/VAN‐P, 45% (1057/2356); Salience/VAN‐A, 28% (713/2523); Visual Med, 24% (574/2375); DMN/Language, 23% (519/2259); FPC R, 21% (729/3403); Visual Lat, 15% (231/1518); DAN, 14% (254/1769); FPC L, 11% (226/2143); DMN‐A, 11% (208/1951); Motor, 10% (305/2998); DMN‐V, 10% (158/1581); Visual Up Med, 7% (77/1150); Somatosensory, 6% (151/2716); DMN‐D, 5% (46/926);</td></tr><tr><td align="left">12–02</td><td align="left">TD &gt; ASD</td><td align="char" char=".">5,126</td><td align="char" char=".">8</td><td align="left">DMN/Language, 39% (875/2259); Salience/VAN‐A, 28% (699/2523); DMN‐A, 23% (455/1951); Auditory/VAN‐P, 21% (484/2356); DMN‐V, 19% (294/1581); DMN‐D, 18% (166/926); FPC R, 16% (545/3403); Visual Med, 15% (363/2375); Visual Lat, 14% (217/1518); FPC L, 12% (257/2143); Visual Up Med, 11% (124/1150); Motor, 11% (332/2998); DAN, 9% (155/1769); Somatosensory, 6% (158/2716);</td></tr><tr><td align="left">05–02</td><td align="left">TD &gt; ASD</td><td align="char" char=".">4,863</td><td align="char" char=".">9</td><td align="left">DMN‐V, 40% (632/1581); DMN‐A, 40% (776/1951); DMN‐D, 39% (364/926); DMN/Language, 27% (603/2259); FPC R, 25% (859/3403); Visual Med, 16% (384/2375); Salience/VAN‐A, 12% (301/2523); Visual Up Med, 11% (123/1150); Visual Lat, 11% (168/1518); FPC L, 11% (246/2143); Auditory/VAN‐P, 8% (180/2356); DAN, 6% (114/1769); Motor, 2% (67/2998); Somatosensory, 1% (36/2716);</td></tr><tr><td align="left">19–18</td><td align="left">ASD &gt; TD</td><td align="char" char=".">4,693</td><td align="char" char=".">19</td><td align="left">Auditory/VAN‐P, 38% (907/2356); FPC R, 26% (894/3403); DMN/Language, 26% (579/2259); DMN‐V, 19% (299/1581); DMN‐D, 19% (173/926); Somatosensory, 15% (412/2716); Motor, 14% (425/2998); Salience/VAN‐A, 13% (317/2523); DMN‐A, 12% (228/1951); FPC L, 11% (234/2143); Visual Up Med, 7% (78/1150); Visual Med, 3% (76/2375); Visual Lat, 2% (36/1518); DAN, 2% (35/1769);</td></tr><tr><td align="left">09–08</td><td align="left">ASD &gt; TD</td><td align="char" char=".">4,525</td><td align="char" char=".">13</td><td align="left">Somatosensory, 34% (915/2716); Visual Up Med, 28% (321/1150); DMN‐V, 24% (375/1581); Visual Med, 20% (481/2375); Motor, 17% (502/2998); Visual Lat, 15% (231/1518); FPC L, 15% (322/2143); DAN, 13% (223/1769); Auditory/VAN‐P, 13% (304/2356); DMN‐A, 11% (220/1951); DMN‐D, 10% (93/926); Salience/VAN‐A, 9% (236/2523); DMN/Language, 8% (188/2259); FPC R, 3% (108/3403);</td></tr><tr><td align="left">04–03</td><td align="left">ASD &gt; TD</td><td align="char" char=".">4,472</td><td align="char" char=".">18</td><td align="left">DMN/Language, 28% (630/2259); Somatosensory, 23% (614/2716); FPC R, 21% (708/3403); DMN‐V, 21% (328/1581); Motor, 19% (568/2998); DMN‐D, 17% (156/926); Visual Up Med, 14% (157/1150); FPC L, 11% (227/2143); Auditory/VAN‐P, 10% (236/2356); Visual Med, 9% (223/2375); DMN‐A, 9% (185/1951); Salience/VAN‐A, 8% (200/2523); DAN, 8% (143/1769); Visual Lat, 6% (89/1518);</td></tr><tr><td align="left">16–06</td><td align="left">TD &gt; ASD</td><td align="char" char=".">4,426</td><td align="char" char=".">35</td><td align="left">DMN‐D, 46% (426/926); DMN‐A, 32% (622/1951); DMN‐V, 29% (459/1581); DMN/Language, 24% (542/2259); FPC R, 20% (695/3403); Auditory/VAN‐P, 20% (477/2356); Visual Lat, 11% (163/1518); FPC L, 10% (210/2143); Visual Med, 8% (179/2375); Somatosensory, 8% (216/2716); Motor, 7% (213/2998); DAN, 5% (81/1769); Salience/VAN‐A, 4% (103/2523); Visual Up Med, 3% (39/1150);</td></tr><tr><td align="left">03–03</td><td align="left">TD &gt; ASD</td><td align="char" char=".">4,187</td><td align="char" char=".">17</td><td align="left">Visual Med, 28% (667/2375); DAN, 26% (452/1769); Somatosensory, 24% (652/2716); Auditory/VAN‐P, 21% (487/2356); DMN‐V, 19% (301/1581); Visual Up Med, 14% (160/1150); Motor, 14% (426/2998); DMN/Language, 12% (263/2259); DMN‐D, 11% (103/926); Visual Lat, 9% (134/1518); FPC R, 7% (246/3403); Salience/VAN‐A, 6% (140/2523); FPC L, 4% (94/2143); DMN‐A, 3% (62/1951);</td></tr><tr><td align="left">05–05</td><td align="left">ASD &gt; TD</td><td align="char" char=".">4,151</td><td align="char" char=".">20</td><td align="left">Auditory/VAN‐P, 41% (971/2356); Salience/VAN‐A, 18% (450/2523); Motor, 18% (534/2998); Visual Med, 15% (358/2375); Somatosensory, 15% (401/2716); FPC L, 15% (319/2143); DMN/Language, 15% (345/2259); FPC R, 11% (384/3403); DAN, 10% (173/1769); DMN‐V, 4% (69/1581); DMN‐D, 4% (33/926); Visual Lat, 3% (51/1518); Visual Up Med, 2% (26/1150); DMN‐A, 2% (37/1951);</td></tr><tr><td align="left">26–16</td><td align="left">TD &gt; ASD</td><td align="char" char=".">3,768</td><td align="char" char=".">16</td><td align="left">FPC L, 35% (748/2143); Salience/VAN‐A, 27% (682/2523); Somatosensory, 23% (620/2716); DAN, 20% (351/1769); Auditory/VAN‐P, 13% (296/2356); DMN‐V, 11% (176/1581); FPC R, 8% (257/3403); DMN‐A, 8% (149/1951); Visual Up Med, 7% (83/1150); DMN/Language, 6% (131/2259); Motor, 5% (162/2998); Visual Lat, 3% (42/1518); DMN‐D, 3% (25/926); Visual Med, 2% (46/2375);</td></tr><tr><td align="left">21–18</td><td align="left">TD &gt; ASD</td><td align="char" char=".">3,663</td><td align="char" char=".">18</td><td align="left">FPC R, 25% (866/3403); DMN‐A, 25% (483/1951); Visual Lat, 23% (345/1518); Visual Med, 21% (498/2375); DMN‐V, 17% (273/1581); DMN‐D, 15% (141/926); FPC L, 14% (291/2143); DAN, 10% (179/1769); Salience/VAN‐A, 9% (238/2523); Visual Up Med, 8% (89/1150); DMN/Language, 4% (86/2259); Motor, 3% (80/2998); Auditory/VAN‐P, 2% (42/2356); Somatosensory, 1% (39/2716);</td></tr><tr><td align="left">13–03</td><td align="left">TD &gt; ASD</td><td align="char" char=".">3,564</td><td align="char" char=".">6</td><td align="left">DMN‐D, 31% (289/926); Visual Med, 29% (681/2375); Auditory/VAN‐P, 26% (609/2356); Salience/VAN‐A, 18% (455/2523); FPC R, 13% (434/3403); DMN/Language, 13% (300/2259); DMN‐A, 11% (217/1951); DMN‐V, 9% (144/1581); DAN, 8% (134/1769); FPC L, 6% (131/2143); Visual Up Med, 4% (43/1150); Motor, 3% (83/2998); Visual Lat, 2% (31/1518); Somatosensory, 0% (11/2716);</td></tr><tr><td align="left">12–07</td><td align="left">TD &gt; ASD</td><td align="char" char=".">3,538</td><td align="char" char=".">21</td><td align="left">Visual Lat, 31% (466/1518); DMN‐A, 31% (608/1951); DMN‐D, 24% (220/926); FPC R, 22% (733/3403); Visual Med, 18% (421/2375); DMN‐V, 15% (233/1581); DAN, 9% (165/1769); Salience/VAN‐A, 8% (213/2523); FPC L, 8% (170/2143); DMN/Language, 6% (134/2259); Visual Up Med, 5% (63/1150); Auditory/VAN‐P, 3% (59/2356); Somatosensory, 1% (21/2716); Motor, 1% (23/2998);</td></tr></tbody></table></div>John Wiley &amp; Sons, Ltd</transformed-table></extracted-table></extracted-tables-set>